Xencor/XNCR

$23.47

-1.47%
-
1D1W1MYTD1YMAX

About Xencor

Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies and cytokine therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs. It uses protein engineering capabilities to enable its understanding of protein structures and interactions and to design technologies and XmAb drug candidates with improved properties. It is advancing its XmAb drug candidates into clinical-stage development. It is focused on the Fc domain, which is part of an antibody that interacts with various segments of the immune system and controls antibody structural architecture. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Vudalimab, XmAb104, XmAb564, XmAb819, XmAb808, Plamotamab, Obexelimab, Sotrovimab, XmAb306/RG6323, and others.

Ticker

XNCR

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Bassil Dahiyat

Employees

280

Headquarters

Pasadena, United States
Website
xencor.com

Xencor Metrics

BasicAdvanced
$1.45B
Market cap
-
P/E ratio
-$2.10
EPS
0.76
Beta
-
Dividend rate

What the Analysts think about Xencor

Analyst Ratings

Majority rating from 13 analysts.
Buy

Price Targets

Average projection from 12 analysts.
62.25% upside
High $59.00
Low $22.00
$23.47
Current price
$38.08
Average price target

Xencor Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-42.82% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$44.6M
-24.53%
Net income
$-19.1M
-21.07%
Profit margin
-42.82%
4.59%

Xencor Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 250.43%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$1.02
-$0.37
-$0.40
-$0.31
-
Expected
-$0.66
-$0.80
-$0.73
-$0.09
-$0.81
Surprise
53.88%
-53.59%
-44.94%
250.43%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Xencor stock

Buy or sell Xencor stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing